Briat Arnaud, Vassaux Georges
Centre for Molecular Oncology, Institute of Cancer and the CR-UK Clinical Centre, Barts and The London, Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, London, EC1M 6BQ, UK.
Expert Rev Mol Med. 2006 Jul 14;8(16):1-19. doi: 10.1017/S1462399406000044.
Gene therapy is a very attractive strategy in experimental cancer therapy. Ideally, the approach aims to deliver therapeutic genes selectively to cancer cells. However, progress in the improvement of gene therapy formulations has been hampered by difficulties in measuring transgene delivery and in quantifying transgene expression in vivo. In clinical trials, endpoints rely almost exclusively on the analysis of biopsies by molecular and histopathological methods, which provide limited information. Therefore, to ensure the rational development of gene therapy, a crucial issue is the utilisation of technologies for the non-invasive monitoring of spatial and temporal gene expression in vivo upon administration of a gene delivery vector. Such imaging technologies would allow the generation of quantitative information about gene expression and the assessment of cancer gene therapy efficacy. In the past decade, progress has been made in the field of in vivo molecular imaging. This review highlights the various methods currently being developed in preclinical models.
基因治疗在实验性癌症治疗中是一种非常有吸引力的策略。理想情况下,该方法旨在将治疗性基因选择性地递送至癌细胞。然而,由于在体内测量转基因递送和定量转基因表达存在困难,基因治疗制剂的改进进展受到了阻碍。在临床试验中,终点几乎完全依赖于通过分子和组织病理学方法对活检样本的分析,而这些方法提供的信息有限。因此,为确保基因治疗的合理发展,一个关键问题是利用技术对基因递送载体给药后体内基因表达的时空进行无创监测。此类成像技术将能够生成有关基因表达的定量信息,并评估癌症基因治疗的疗效。在过去十年中,体内分子成像领域取得了进展。本综述重点介绍了目前在临床前模型中正在开发的各种方法。